Stivarga Regulatory Post-Marketing Surveillance Study in Korea

Trial Profile

Stivarga Regulatory Post-Marketing Surveillance Study in Korea

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer; Gastrointestinal stromal tumours
  • Focus Adverse reactions
  • Acronyms StivargaPMS
  • Sponsors Bayer
  • Most Recent Events

    • 11 Apr 2017 Planned number of patients changed from 3750 to 190.
    • 23 Jun 2016 Planned End Date changed from 1 Aug 2019 to 1 May 2019.
    • 07 Mar 2016 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top